BOOTHBAY FUND MANAGEMENT, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 110 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2022. The put-call ratio across all filers is 0.38 and the average weighting 0.1%.

Quarter-by-quarter ownership
BOOTHBAY FUND MANAGEMENT, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$111,840
+29.0%
74,560
+0.6%
0.00%0.0%
Q4 2022$86,690
+97.0%
74,094
+166.7%
0.00%
+100.0%
Q2 2022$44,000
+25.7%
27,777
+94.8%
0.00%0.0%
Q4 2021$35,00014,2580.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2022
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders